Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FQJX4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $66,883
Award facts
- Contract value 100% obligated
- $66,883.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $66,883.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. The delivery order, issued on January 30, 2026, with an ultimate completion date of February 23, 2026, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $499.999 billion ceiling value and performance period extending through December 31, 2036.
DMS Pharmaceutical Group's role as a PPV-G GEN V regional prime vendor positions it as a critical supplier within the Department of Defense's global military healthcare pharmaceutical supply chain. The company's established track record of delivering diverse pharmaceutical products—ranging from specialty biologics and oncology treatments to routine medications and medical devices—demonstrates its capability to fulfill specialized federal medical supply requirements. The Nexplanon implant delivery represents routine execution of the broader PPV-G GEN V acquisition strategy, which is structured to provide DLA and military healthcare facilities worldwide with reliable access to comprehensive pharmaceutical and medical consumable products through pre-established vendor relationships.
Quick answers
Who was awarded contract SPE2DR26FQJX4?
SPE2DR26FQJX4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FQJX4 worth?
The government has obligated $66,883 on SPE2DR26FQJX4.
Is contract SPE2DR26FQJX4 an order under another contract?
Yes. SPE2DR26FQJX4 is a delivery order under SPE2DR25D9135, an indefinite delivery contract.
Was contract SPE2DR26FQJX4 competed?
The extent of competition for SPE2DR26FQJX4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award